Enanta Pharmaceuticals to Host Conference Call on May 7th at 4:30 pm ET to Discuss Its Financial Results for Its Fiscal Second Quarter Ended March 31, 2019

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that it plans to report its financial results for its fiscal second
quarter ended March 31, 2019 after the U.S. markets close on May 7,
2019. Enanta management will host a conference call at 4:30 p.m. ET to
discuss these results and provide an update on Enanta’s business,
including its research and development pipeline.

Conference Call and Webcast Information
Enanta will host a
conference call and webcast on May 7 at 4:30 p.m. ET. To participate in
the live conference call, please dial (855) 840-0595 in the U.S. or
(518) 444-4814 for international callers. A replay of the conference
call will be available starting at approximately 7:30 p.m. ET on May 7,
2019, through 11:59 p.m. ET on May 8, 2019 by dialing (855) 859-2056
from the U.S. or (404) 537-3406 for international callers. The passcode
for both the live call and the replay is 1191209. A live audio webcast
of the call and replay can be accessed by visiting the “Events and
Presentation” section on the “Investors” page of Enanta’s website at www.enanta.com.

About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals is
using its robust, chemistry-driven approach and drug discovery
capabilities to become a leader in the discovery and development of
small molecule drugs for the treatment of viral infections and liver
diseases. Enanta’s research and development efforts are currently
focused on the following disease targets: respiratory syncytial virus
(RSV), non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis
(PBC), and hepatitis B virus (HBV).

Enanta’s research and development activities are funded by royalties
from HCV products developed under its collaboration with AbbVie.
Glecaprevir, discovered by Enanta, is the second protease inhibitor
developed under the collaboration and is sold by AbbVie in numerous
countries as part of its newest treatment for chronic hepatitis C virus
(HCV) infection. This leading HCV regimen is sold under the tradenames
MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir).
Please visit www.enanta.com
for more information.


Investor Contact:
Carol Miceli
[email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.